Dr Paul Blake becomes Chief Development Officer at Oxford BioMedica

Will take responsibility for the clinical development of pipeline of gene and cell therapies

Oxford BioMedica, a UK developer of gene-based medicines and therapeutic vaccines, has appointed Dr Paul Blake to the Executive Management team as Chief Development Officer, with effect from 1 September 2014. Blake, previously a Non-Executive Director of the company, will remain a member of the Board and take responsibility for the clinical development of Oxford BioMedica’s pipeline of gene and cell therapies.

Blake joined the Board of Oxford BioMedica in January 2010. He is a senior pharmaceutical executive with more than 30 years’ experience gained from roles in international pharmaceutical and biotech companies and he has been involved in the development of many drugs and vaccines including Parkinson's Disease treatment Requip, heart treatment Coreg and sleepiness drug Provigil.

Most recently, Blake was Senior Vice President and Chief Medical Officer of Æterna Zentaris.

You may also like

Hi Tech Manufacturing

Oxford Biomedica partners with Microsoft to improve yield of gene therapy via machine learning

Collaboration will see the computing expert develop in silico models and algorithms to address the manufacturing challenges of novel therapies
Recruitment

CGT Catapult addresses skills gap with apprenticeship programme for advanced therapies

Programme will address the projected skills shortage facing public and private employers in the growing cell and gene therapy sector
Design & Build

Oxford BioMedica receives MHRA GMP manufacturing approvals

For lentiviral gene therapy bioprocessing and process development
Design & Build

WHP completes bio-manufacturing facility for Oxford BioMedica

Additional cleanroom space took less than 12 months from concept to completion and creates extra capacity
Research & Development

UK biotechs win Biomedical Catalyst funding of almost £100m

Thirty-three UK companies have received business-led awards
Research & Development

Oxford BioMedica signs LentiVector agreement with GSK

For the development of six product candidates targeting rare orphan diseases
Research & Development

Oxford BioMedica collaborates with Novartis

Expects to receive between £2.5m and £4m over next 12 months
Subscribe now